Form 4: Guardant Health Director Sells Shares Following RSU Vesting

Myrtle S. Potter, a director at Guardant Health, Inc., reported the acquisition of common stock through Restricted Stock Unit (RSU) vesting and a subsequent sale of shares.

Summary

• Myrtle S. Potter, a Director of Guardant Health, Inc. (GH), reported transactions involving the company's common stock.
• On June 12, 2025, Ms. Potter acquired 6,674 shares of common stock at a price of $0, resulting from the vesting of Restricted Stock Units (RSUs). These RSUs were granted on June 12, 2024, and vest on the one-year anniversary of the grant date or the date of the next annual stockholders meeting, whichever is earlier.
• On June 15, 2025, Ms. Potter acquired an additional 69 shares of common stock at a price of $0, also due to RSU vesting. These RSUs vested 25% on October 15, 2022, with the remaining 75% vesting in substantially equal monthly installments over three years from that date.
• Following these acquisitions, Ms. Potter's beneficial ownership of common stock increased to 20,806 shares.
• On June 16, 2025, Ms. Potter disposed of 2,626 shares of common stock through a sale at a price of $49.70 per share.
• After all reported transactions, Ms. Potter's direct beneficial ownership of common stock stands at 18,180 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a director selling shares can sometimes be viewed negatively, this appears to be a routine transaction involving the vesting of Restricted Stock Units (RSUs) and a subsequent sale, likely for tax purposes or portfolio diversification, as indicated by the Rule 10b5-1 plan. The acquisition of shares through vesting at a $0 cost is a positive for the insider.

Positives

• The vesting of Restricted Stock Units (RSUs) at a $0 acquisition price represents a gain for the director, as these shares are essentially compensation.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan rather than a discretionary sale based on immediate market views.

Negatives

• A director selling shares, even if pre-planned, can sometimes be perceived by investors as a lack of confidence or a move to diversify, potentially signaling a less bullish outlook.

Risks

• No specific risks are detailed in this Form 4 filing beyond the inherent market risks associated with stock ownership and trading.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape for Guardant Health, Inc. It reflects a director's compensation and personal portfolio management.

Stakeholder Impact

• Shareholders: May observe the director's sale of shares, which could be interpreted in various ways, though the Rule 10b5-1 plan suggests it's not based on new, non-public information.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, Director Stock Sale, Restricted Stock Units, RSU Vesting, Stock Transaction, Corporate Governance